{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:37:03Z","timestamp":1780659423053,"version":"3.54.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA205437"],"award-info":[{"award-number":["CA205437"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PA Breast Cancer Coalition"},{"name":"Phi Beta Psi Sorority National Project"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA205437"],"award-info":[{"award-number":["CA205437"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Carboplatin is a chemotherapy drug used to treat solid tumors but also causes bone loss and muscle atrophy and weakness. Bone loss contributes to muscle weakness through bone-muscle crosstalk, which is prevented with the bisphosphonate zoledronic acid (ZA). We treated mice with carboplatin in the presence or absence of ZA to assess the impact of bone resorption on muscle. Carboplatin caused loss of body weight, muscle mass, and bone mass, and also led to muscle weakness as early as 7\u2009days after treatment. Mice treated with carboplatin and ZA lost body weight and muscle mass but did not lose bone mass. In addition, muscle function in mice treated with ZA was similar to control animals. We also used the anti-TGF\u03b2 antibody (1D11) to prevent carboplatin-induced bone loss and showed similar results to ZA-treated mice. We found that atrogin-1 mRNA expression was increased in muscle from mice treated with carboplatin, which explained muscle atrophy. In mice treated with carboplatin for 1 or 3\u2009days, we did not observe any bone or muscle loss, or muscle weakness. In addition, reduced caloric intake in the carboplatin treated mice did not cause loss of bone or muscle mass, or muscle weakness. Our results show that blocking carboplatin-induced bone resorption is sufficient to prevent skeletal muscle weakness and suggests another benefit to bone therapy beyond bone in patients receiving chemotherapy. \u00a9 2019 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3890","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T22:55:23Z","timestamp":1571180123000},"page":"368-381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy"],"prefix":"10.1093","volume":"35","author":[{"given":"Brian A","family":"Hain","sequence":"first","affiliation":[{"name":"Department of Cellular and Molecular Physiology The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Jude","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Physiology The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Physiology The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas M","family":"Smuin","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Rehabilitation The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Fox","sequence":"additional","affiliation":[{"name":"Center for Orthopaedic Research and Translational Science Hershey PA USA"},{"name":"Department of Orthopaedics and Rehabilitation The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Elfar","sequence":"additional","affiliation":[{"name":"Center for Orthopaedic Research and Translational Science Hershey PA USA"},{"name":"Department of Orthopaedics and Rehabilitation The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-7623","authenticated-orcid":false,"given":"David L","family":"Waning","sequence":"additional","affiliation":[{"name":"Penn State Cancer Institute Hershey PA USA"},{"name":"Center for Orthopaedic Research and Translational Science Hershey PA USA"},{"name":"Department of Cellular and Molecular Physiology The Penn State College of Medicine Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2024031418584206900_jbmr3890-bib-0001","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024031418584206900_jbmr3890-bib-0002","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1152\/japplphysiol.00790.2012","article-title":"The mechanisms of cachexia underlying muscle dysfunction in COPD","volume":"114","author":"Remels","year":"2013","journal-title":"J Appl Physiol"},{"issue":"Suppl 2","key":"2024031418584206900_jbmr3890-bib-0003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000227129","article-title":"HIV-related cachexia: potential mechanisms and treatment","volume":"49","author":"Von Roenn","year":"1992","journal-title":"Oncology"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcsm.12167","article-title":"Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016","volume":"7","author":"von Haehling","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"2024031418584206900_jbmr3890-bib-0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: mechanisms and therapies","volume":"14","author":"von Haehling","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11912-017-0562-0","article-title":"Update on management of cancer-related cachexia","volume":"19","author":"Anderson","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"2024031418584206900_jbmr3890-bib-0007","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00520-017-4022-z","article-title":"A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer","volume":"26","author":"Vagnildhaug","year":"2018","journal-title":"Support Care Cancer"},{"key":"2024031418584206900_jbmr3890-bib-0008","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Li","year":"2018","journal-title":"Dalton Trans"},{"key":"2024031418584206900_jbmr3890-bib-0009","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11864-013-0266-0","article-title":"When and how do I use Neoadjuvant chemotherapy for breast cancer?","volume":"15","author":"Rapoport","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"2024031418584206900_jbmr3890-bib-0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.drup.2005.04.006","article-title":"Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs","volume":"8","author":"Brabec","year":"2005","journal-title":"Drug Resist Updat"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2617-1619.2019.tb00011.x","article-title":"Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia","volume":"2","author":"Hain","year":"2019","journal-title":"JCSM Rapid Commun"},{"key":"2024031418584206900_jbmr3890-bib-0012","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-beta mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat Med"},{"issue":"11","key":"2024031418584206900_jbmr3890-bib-0013","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2014-1722","article-title":"Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment","volume":"99","author":"Willemse","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024031418584206900_jbmr3890-bib-0014","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11914-011-0059-y","article-title":"The role of falls in fracture prediction","volume":"9","author":"Bischoff-Ferrari","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"2024031418584206900_jbmr3890-bib-0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00774-015-0679-x","article-title":"Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats","volume":"34","author":"Fan","year":"2016","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0017","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.1038\/s41598-017-15040-1","article-title":"ACVR2B\/Fc counteracts chemotherapy-induced loss of muscle and bone mass","volume":"7","author":"Barreto","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"2024031418584206900_jbmr3890-bib-0018","doi-asserted-by":"crossref","first-page":"e78043","DOI":"10.1371\/journal.pone.0078043","article-title":"Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta","volume":"8","author":"Rana","year":"2013","journal-title":"PLoS One"},{"key":"2024031418584206900_jbmr3890-bib-0019","first-page":"89","article-title":"Role of zoledronic acid in the prevention and treatment of osteoporosis","volume":"6","author":"Rakel","year":"2011","journal-title":"Clin Interv Aging"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"issue":"8","key":"2024031418584206900_jbmr3890-bib-0021","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Invest"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12018-016-9226-0","article-title":"Clinical and genetic advances in Paget's disease of bone: a review","volume":"15","author":"Alonso","year":"2017","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0023","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","article-title":"The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo","volume":"1","author":"Fleisch","year":"1970","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"2024031418584206900_jbmr3890-bib-0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2024031418584206900_jbmr3890-bib-0026","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bonekey.2013.1","article-title":"Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Clezardin","year":"2013","journal-title":"Bonekey Rep"},{"issue":"38","key":"2024031418584206900_jbmr3890-bib-0027","doi-asserted-by":"crossref","first-page":"16098","DOI":"10.1073\/pnas.1109546108","article-title":"Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4","volume":"108","author":"Sun","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0028","first-page":"26","article-title":"The proteolytic systems of muscle wasting","volume":"9","author":"Scicchitano","year":"2015","journal-title":"Recent Adv DNA Gene Seq"},{"key":"2024031418584206900_jbmr3890-bib-0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/840951","article-title":"Taurine rescues cisplatin-induced muscle atrophy in vitro: a morphological study","volume":"2014","author":"Stacchiotti","year":"2014","journal-title":"Oxid Med Cell Longev"},{"issue":"11","key":"2024031418584206900_jbmr3890-bib-0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00424-017-2045-4","article-title":"Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse","volume":"469","author":"Sakai","year":"2017","journal-title":"Pflugers Archiv"},{"key":"2024031418584206900_jbmr3890-bib-0031","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fphys.2017.00788","article-title":"mTOR as a key regulator in maintaining skeletal muscle mass","volume":"8","author":"Yoon","year":"2017","journal-title":"Front Physiol"},{"issue":"9","key":"2024031418584206900_jbmr3890-bib-0032","doi-asserted-by":"crossref","first-page":"e24650","DOI":"10.1371\/journal.pone.0024650","article-title":"The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/+) mouse","volume":"6","author":"White","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2044-5040-3-6","article-title":"Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy","volume":"3","author":"Bentzinger","year":"2013","journal-title":"Skelet Muscle"},{"issue":"10","key":"2024031418584206900_jbmr3890-bib-0034","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.biocel.2013.05.039","article-title":"Regulation of muscle protein synthesis and the effects of catabolic states","volume":"45","author":"Gordon","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0036","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/0284186X.2014.953259","article-title":"Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer","volume":"54","author":"Stene","year":"2015","journal-title":"Acta Oncol"},{"issue":"23","key":"2024031418584206900_jbmr3890-bib-0037","first-page":"6297","article-title":"Comparative pharmacokinetics of cisplatin and three analogues in mice and humans","volume":"47","author":"van Hennik","year":"1987","journal-title":"Cancer Res"},{"key":"2024031418584206900_jbmr3890-bib-0038","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/bonekey.2015.101","article-title":"Assessment of muscle mass and strength in mice","volume":"4","author":"Bonetto","year":"2015","journal-title":"Bonekey Rep"},{"issue":"11","key":"2024031418584206900_jbmr3890-bib-0039","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/art.24907","article-title":"Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis","volume":"60","author":"Yamada","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1152\/japplphysiol.00762.2017","article-title":"MyoVision: software for automated high-content analysis of skeletal muscle immunohistochemistry","volume":"124","author":"Wen","year":"2018","journal-title":"J Appl Physiol"},{"issue":"11","key":"2024031418584206900_jbmr3890-bib-0041","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.139","article-title":"Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo","volume":"25","author":"Edwards","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0042","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/jnen\/60.3.302","article-title":"Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment?","volume":"60","author":"Sandri","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"2024031418584206900_jbmr3890-bib-0043","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1054\/bjoc.2001.1700","article-title":"Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia","volume":"84","author":"Belizario","year":"2001","journal-title":"Br J Cancer"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0044","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00520-016-3545-z","article-title":"Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life","volume":"25","author":"Rha","year":"2017","journal-title":"Support Care Cancer"},{"issue":"6","key":"2024031418584206900_jbmr3890-bib-0045","first-page":"767","article-title":"Bone loss during neoadjuvant\/adjuvant chemotherapy for early stage breast cancer: a retrospective cohort study","volume":"8","author":"Axelsen","year":"2018","journal-title":"Mol Clin Oncol"},{"issue":"10","key":"2024031418584206900_jbmr3890-bib-0046","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"issue":"15","key":"2024031418584206900_jbmr3890-bib-0047","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0048","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/fon-2017-0403","article-title":"Denosumab for the treatment of bone disease in solid tumors and multiple myeloma","volume":"14","author":"Yee","year":"2018","journal-title":"Future Oncol"},{"issue":"6","key":"2024031418584206900_jbmr3890-bib-0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ecc.12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1078-0432.CCR-16-0162","article-title":"Efficacy of Neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024031418584206900_jbmr3890-bib-0051","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2024031418584206900_jbmr3890-bib-0052","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/jcp.23034","article-title":"The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss","volume":"227","author":"Shandala","year":"2012","journal-title":"J Cell Physiol"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0053","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jor.22527","article-title":"Cisplatin inhibits bone healing during distraction osteogenesis","volume":"32","author":"Stine","year":"2014","journal-title":"J Orthop Res"},{"issue":"2","key":"2024031418584206900_jbmr3890-bib-0054","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jcpe.12824","article-title":"Cisplatin chemotherapy impairs the peri-implant bone repair around titanium implants: an in vivo study in rats","volume":"45","author":"Matheus","year":"2018","journal-title":"J Clin Periodontol"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","article-title":"Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis","volume":"332","author":"Manolagas","year":"1995","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"2024031418584206900_jbmr3890-bib-0056","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10555-012-9372-x","article-title":"Genes associate with abnormal bone cell activity in bone metastasis","volume":"31","author":"Roodman","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"2024031418584206900_jbmr3890-bib-0057","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/bonekey.2015.59","article-title":"Cancer-associated muscle weakness: what's bone got to do with it?","volume":"4","author":"Waning","year":"2015","journal-title":"Bonekey Rep"},{"issue":"1\u20132","key":"2024031418584206900_jbmr3890-bib-0058","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0303-7207(01)00496-8","article-title":"Involvement of activin in the regulation of bone metabolism","volume":"180","author":"Sakai","year":"2001","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2024031418584206900_jbmr3890-bib-0059","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1008231925889","article-title":"Carboplatin toxic effects on the peripheral nervous system of the rat","volume":"9","author":"Cavaletti","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1345\/aph.1E319","article-title":"Oxaliplatin-associated neuropathy: a review","volume":"39","author":"Cersosimo","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2024031418584206900_jbmr3890-bib-0061","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J Neurol"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0062","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/jcsm.12218","article-title":"Vitamin D, a modulator of musculoskeletal health in chronic kidney disease","volume":"8","author":"Molina","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"2024031418584206900_jbmr3890-bib-0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(98)70152-0","article-title":"Carboplatin-related hematuria and acute renal failure","volume":"32","author":"Agraharkar","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2024031418584206900_jbmr3890-bib-0064","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jsbmb.2017.03.018","article-title":"Vitamin D and muscle function","volume":"173","author":"Dawson-Hughes","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2024031418584206900_jbmr3890-bib-0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.beem.2011.05.002","article-title":"The effect of vitamin D on bone and osteoporosis","volume":"25","author":"Lips","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024031418584206900_jbmr3890-bib-0066","first-page":"1","article-title":"Mice with myocyte deletion of vitamin D receptor have sarcopenia and impaired muscle function","author":"Girgis","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2024031418584206900_jbmr3890-bib-0067","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcsm.12185","article-title":"Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia","volume":"8","author":"Conte","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"2024031418584206900_jbmr3890-bib-0068","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11154-017-9424-1","article-title":"The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention","volume":"18","author":"Holick","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2024031418584206900_jbmr3890-bib-0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu9040328","article-title":"Vitamin D in chronic kidney disease and dialysis patients","volume":"9","author":"Jean","year":"2017","journal-title":"Nutrients"},{"issue":"4","key":"2024031418584206900_jbmr3890-bib-0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024031418584206900_jbmr3890-bib-0071","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jss.2012.10.033","article-title":"Differential effect of zoledronic acid on human vascular smooth muscle cells","volume":"182","author":"Albadawi","year":"2013","journal-title":"J Surg Res"},{"issue":"2","key":"2024031418584206900_jbmr3890-bib-0072","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-012-0041-1","article-title":"Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice","volume":"33","author":"Sieber","year":"2013","journal-title":"Clin Drug Investig"},{"key":"2024031418584206900_jbmr3890-bib-0073","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.4081\/ejtm.2018.7590","article-title":"Chemotherapy-induced muscle wasting: association with NF-\u03baB and cancer cachexia","volume":"28","author":"Damrauer","year":"2018","journal-title":"Eur J Transl Myol"},{"issue":"3","key":"2024031418584206900_jbmr3890-bib-0074","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.taap.2010.11.003","article-title":"Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems","volume":"250","author":"Fanzani","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"issue":"14","key":"2024031418584206900_jbmr3890-bib-0075","doi-asserted-by":"crossref","first-page":"24009","DOI":"10.18632\/oncotarget.15103","article-title":"Protein calorie malnutrition, nutritional intervention and personalized cancer care","volume":"8","author":"Gangadharan","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2024031418584206900_jbmr3890-bib-0076","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-133-8-200010170-00015","article-title":"Cachexia","volume":"133","author":"Kotler","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024031418584206900_jbmr3890-bib-0077","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2014.05.001","article-title":"Mechanisms of cisplatin-induced muscle atrophy","volume":"278","author":"Sakai","year":"2014","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3890","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/2\/368\/55457412\/jbmr3890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/2\/368\/55457412\/jbmr3890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:00:17Z","timestamp":1710442817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/35\/2\/368\/7516338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,15]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3890","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"2019-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}